News | Cardiac Imaging | June 14, 2021

Deep Learning Enables Dual Screening for Cancer and Cardiovascular Disease

Rensselaer algorithm can identify risk of cardiovascular disease using lung cancer scan #CT

June 14, 2021 — Heart disease and cancer are the leading causes of death in the United States, and it’s increasingly understood that they share common risk factors, including tobacco use, diet, blood pressure, and obesity. Thus, a diagnostic tool that could screen for cardiovascular disease while a patient is already being screened for cancer, has the potential to expedite a diagnosis, accelerate treatment, and improve patient outcomes. 

In research published today in Nature Communications, a team of engineers from Rensselaer Polytechnic Institute and clinicians from Massachusetts General Hospital developed a deep learning algorithm that can help assess a patient’s risk of cardiovascular disease with the same low-dose computerized tomography (CT) scan used to screen for lung cancer. This approach paves the way for more efficient, more cost-effective, and lower radiation diagnoses, without requiring patients to undergo a second CT scan. 

“In this paper, we demonstrate very good performance of a deep learning algorithm in identifying patients with cardiovascular diseases and predicting their mortality risks, which shows promise in converting lung cancer screening low-dose CT into a dual screening tool,” said Pingkun Yan, an assistant professor of biomedical engineering and member of the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselaer.

Numerous hurdles had to be overcome in order to make this dual screening possible. Low-dose CT images tend to have lower image quality and higher noise, making the features within an image harder to see. Using a large dataset from the National Lung Screening Trial (NLST), Yan and his team used data from more than 30,000 low-dose CT images to develop, train, and validate a deep learning algorithm capable of filtering out unwanted artifacts and noise, and extracting features needed for diagnosis. Researchers validated the algorithm using an additional 2,085 NLST images.

The Rensselaer team also partnered with Massachusetts General Hospital, where researchers were able to test this deep learning approach against state-of-the-art scans and the expertise of the hospital’s radiologists. The Rensselaer-developed algorithm, Yan said, not only proved to be highly effective in analyzing the risk of cardiovascular disease in high-risk patients using low-dose CT scans, but it also proved to be equally effective as radiologists in analyzing those images. In addition, the algorithm closely mimicked the performance of dedicated cardiac CT scans when it was tested on an independent dataset collected from 335 patients at Massachusetts General Hospital.

“This innovative research is a prime example of the ways in which bioimaging and artificial intelligence can be combined to improve and deliver patient care with greater precision and safety,” said Deepak Vashishth, the director of CBIS.

Yan was joined in this work by Ge Wang, an endowed chair professor of biomedical engineering at Rensselaer and fellow member of CBIS. The Rensselaer team was joined by Dr. Mannudeep K. Kalra, an attending radiologist at Massachusetts General Hospital and professor of radiology with Harvard Medical School. This research was funded by the National Institutes of Health National Heart, Lung, and Blood Institute.  

For more information: www.rpi.edu

Related lung and heart disease content:

Lung Cancer Screening Predicts Risk of Death from Heart Disease

Low-dose CT for Lung Cancer Screening: Benefit Outweighs Potential Harm

AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs

Experts Recommend Shared Patient - Doctor Decision-making Prior to Lung Cancer Screening


Related Content

News | Cardiac Imaging

May 1, 2026 — On May 14, Cleerly and interventional cardiologist Neerav Sheth, MD, will present a free webinar on ...

Home May 12, 2026
Home
News | Cardiac Imaging

April 28, 2026 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its next ...

Home April 29, 2026
Home
News | Cardiac Imaging

April 23, 2026 — Royal Philips has launched the next-generation Bridge Plus Occlusion Balloon, designed to help ...

Home April 23, 2026
Home
Feature | Cardiac Imaging | Kyle Hardner

Editor's Note: This is Part One of a three-part series highlighting several of the presentations from the American ...

Home April 23, 2026
Home
News | Cardiac Imaging

April 20, 2026 — Conavi Medical Corp. recently announced that it has received U.S. Food and Drug Administration (FDA) ...

Home April 22, 2026
Home
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Home April 01, 2026
Home
News | Cardiac Imaging

March 18, 2026 — Circle Cardiovascular Imaging (Circle CVI) has announced the expansion of its cvi42 cardiovascular ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 19, 2026 — Heart disease is the leading cause of adult death worldwide, making cardiovascular disease diagnosis ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 16, 2026 — The American Society for Preventive Cardiology (ASPC) will host its 2026 Virtual Imaging Symposium, a ...

Home March 17, 2026
Home
Feature | Cardiac Imaging

Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...

Home March 13, 2026
Home
Subscribe Now